OncBioMune Pharmaceuticals (OTC: OBMP) is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. The company’s lead product, ProscaVax™ is scheduled to commence a phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. For more information, visit the company’s website at www.oncbiomune.com.